Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
crispr
5
×
life sciences
national blog main
boston blog main
boston top stories
national top stories
editas medicine
gene editing
national
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
car-t
clinical study
clinical trials
commissioner
crispr therapeutics
deals
democrats
detroit blog main
detroit top stories
drugs
failure
fda
gene therapy
glaxosmithkline
ipo
katrine bosley
medical devices
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
scott gottlieb
What
crispr
5
×
bio
big
cas
ceo
editas
gene
katrine
medicine
million
roundup
therapeutics
therapy
access
advanced
allergan
allogene
available
based
biosciences
blessing
bosley
bosley's
bosley’s
bridge
bucks
cancer
capacity
car
cell
cheaper
check
clinical
consolidation
crime
cusp
depart
departure
develop
diagnostics
Language
unset
Current search:
crispr
×
crispr
×
biotech
×
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
